Chronic migraine (CM) may be associated with widespread disruption of normal white matter (WM) integrity in the brain, according to a study published in The Journal of Headache and Pain.
Chronic migraine (CM) may be associated with widespread disruption of normal white matter (WM) integrity in the brain, according to a study published in The Journal of Headache and Pain.
Although only a small percentage of individuals with episodic migraine (MO) later develop into chronic migraineurs, research has shown an association between MO and CM and abnormalities in density and thickness of the brain’s grey matter, in addition to functional connectivity at rest or following painful stimulation.
“Some studies have found anomalies in the microstructure of the WM of migraineurs,” authors write. “Two studies reported there to be no remarkable differences in the integrity of WM microstructure between patients with CM and healthy controls (HCs). However, patients were scanned during prevention and/or medication overuse.”
To better understand the relationship between WM and migraine, researchers investigated intracerebral fiber bundles using a tract-based spatial (TBSS) analysis of diffusion tensor imaging (DTI) data to verify microstructural integrity in patients with MO and CM.
“Among the various techniques used to acquire MRI data, DTI is the most sensitive to microstructural changes by estimating the diffusivity of water molecules along the fiber bundles of WM in the 3 main orthogonal directions of diffusion,” authors write.
The study cohort included 19 individuals with MO, 18 patients with CM without any history of drug abuse, and 18 healthy controls. Based on DTI, researchers calculated diffusion metrics including fractional anisotropy (FA), axial diffusion (AD), radial diffusion (RD) and mean diffusion (MD).
“All patients were tested during the interictal period, which was defined as the period at which it had been at least 3 days since the last attack and 3 days before the subsequent attack for the MO group,” authors write.
Analyses showed:
“This study found widespread differences in the organization of WM between patients with CM and HCs,” researchers said, while “the diffusive metrics of episodic migraineurs, which did not differ significantly from those of HCs, also differed significantly from those of patients with CM.”
Small sample sizes may have biased results, acting as a limitation to the study. However, it is difficult to recruit patients with pure CM and without preventive treatment or a history of drug abuse, authors note.
The peculiar microstructural patterns of CM patients may indicate axonal abnormalities, decreased cellular density, and/or loss of directional organization in the WM fiber bundles, researchers hypothesize.
However, “further studies are needed to verify whether this reorganization of WM of the CM brain can be normalized by pharmacological and non-pharmacological interventions.”
Reference
Coppola G, Di Renzo A, Tinelli E, et al. Patients with chronic migraine without history of medication overuse are characterized by a peculiar white matter fiber bundle profile. J Headache Pain. 2020;21(1):92. doi:10.1186/s10194-020-01159-6
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen